Epigenetic silencing of TNFSF7 (CD70) by DNA methylation during progression to breast cancer

Molecules and Cells

Volumn 29, Issue 2, 2010, Pages 217-221

  Yu, Seung Eun ^a   Park, Su Hyung ^a   Jang, Yeun Kyu ^a  

^a Yonsei University   (South Korea)

Author keywords

Co stimulatory molecules; DNA methylation; Epigenetic silencing; Isogenic human breast cancer cell lines; TNFSF7(CD70)

Indexed keywords

CD70 ANTIGEN; DNA;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER GROWTH; CANCER INVASION; CONTROLLED STUDY; DNA METHYLATION; DOWN REGULATION; EPIGENETICS; GENE EXPRESSION REGULATION; GENE SEQUENCE; GENE SILENCING; HUMAN; HUMAN CELL; IMMUNOSURVEILLANCE; PROMOTER REGION; TUMOR ESCAPE; TUMOR IMMUNITY;

ANTIGENS, CD70; AZACITIDINE; BASE SEQUENCE; BREAST NEOPLASMS; CELL LINE, TUMOR; CPG ISLANDS; DISEASE PROGRESSION; DNA METHYLATION; DOWN-REGULATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HUMANS; MOLECULAR SEQUENCE DATA; PROMOTER REGIONS, GENETIC; RNA, MESSENGER;

EID: 77949425245     PISSN: 10168478     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10059-010-0052-9     Document Type: Article

References (23)

1. Baylin, S.B., and Jones, P.A. (2007). Epigenetic determinants of cancer. In Epigenetics, C.D. Allis, T. Jenuwein, and D. Reinberg, eds. (New York, USA: Cold Spring Harbor, Cold Spring Harbor Laboratory Press), pp. 457-476.
2. Borst, J., Hendriks, J., and Xiao, Y. (2005). CD27 and CD70 in T cell and B cell activation. Curr. Opin. Immunol. 17, 275-281.
3. Choi, B., Suh, Y., Kim, W.H., Christa, L., Park, J., and Bae, C.D. (2007). Down-regulation of regenerating islet-derived 3 alpha (REG3A) in primary human gastric adenocarcinomas. Exp. Mol. Med. 39, 796-804.
4. Cormary, C., Gonzalez, R., Faye, J.C., Favre, G., and Tilin-Mariame, A.F. (2004). Induction of T-cell antitumor immunity and protection against tumor growth by secretion of soluble human CD70 molecules. Cancer Gene Ther. 11, 497-507.
5. Diegmann, J., Junker, K., Loncarevic, I.F., Michel, S., Schimmel, B., and Eggeling, Fv. (2006). Immune escape for renal cell carcinoma: CD70 mediates apoptosis in mymphocytes. Neoplasia 8, 933-938.
6. Douin-Echinard, V., Bornes, S., Rochaix, P., Tilkin, A.F., Peron, J.M., Bonnet, J., Favre, G., and Coudere, B. (2000). The expression of CD70 and CD80 by gene-modified tumor cells induces an antitumor response depending on the MHC status. Cancer Gene Ther. 7, 1543-1556.
7. Douin-Echinard, V., Peron, J.M., Lauwers-Cances, V., Favre, G., and Couderc, B. (2003). Involvement of CD70 and CD80 intracytoplasmic domains in the co-stimulatory signal required to provide an antitumor immune response. Int. Immunol. 15, 359-372.
8. Huang, Y., Tan, M., Gosink, M., Wang, K.K.W., and Sun, Y. (2002). Histone deacetylase 5 is not a p53 target gene, but its over-expression inhibits tumor cell growth and induces apoptosis. Cancer Res. 62, 2913-2922.
9. Hurst, D.R., Xie, Y., Edmonds, M.D., and Welch, D.R. (2009). Multiple forms of BRMS1 are differentially expressed in the MCF10 isogenic breast cancer progression model. Clin. Exp. Metastasis 26, 89-96.
10. Kim, J.H., Hwang, E.H., Park, H.J., Paik, Y.K., and Shim, Y.H. (2005). Methylation of CpG islands in the rat 7-dehydrocholesterol reductase promoter suppresses transcriptional activation. Mol. Cells 19, 279-282.
11. Lu, Q., Wu, A., and Richardson, B.C. (2005). Demethylation of the same promoter sequence increases CD70 expression in Lupus T cells and T cells treated with Lupus-inducing drugs. J. Immunol. 174, 6212-6219.
12. Marella, N.V., Malyavantham, K.S., Wang, J., Matsui, S., Liang, P., and Berezney, R. (2009). Cytogenetic and cDNA microarray expression analysis of MCF10 human breast cancer progresssion cell lines. Cancer Res. 69, 5946-5953.
13. Motegi, K., Azuma, M., Tamatani, T., Ashida, Y., and Sato, M. (2005). Expression of aquaporin-5 in and fluid secretion from immortalized human salivary gland ductal cells by treatment with 5-aza-2′-deoxycytidine: a possibility for improvement of xerostomia in patients with Sjogren's syndrome. Lab. Invest. 85, 342-353.
14. Pardoll, D.M. (1998). Cancer vaccines. Nat. Med. 4, 525-531.
15. Park, W.S., Cho, Y.G., Kim, C.J., Song, J.H., Lee, Y.S., Kim, S.Y., Nam, S.W., Lee, S.H., Yoo, N.J., and Lee, J.Y. (2005). Hypermethylation of the RUNX3 gene in hepatocellular carcinoma. Exp. Mol. Med. 37, 276-281.
16. Park, H.Y., Jeon, Y.K., Shin, H.J., Kim, I.J., Kang, H.C., Jeong, S.J., Chung, D.H., and Lee, C.W. (2007). Differential promoter methylation may be a key molecular mechanism in regulating BubR1 expression in cancer cells. Exp. Mol. Med. 39, 195-204.
17. Rhee, D.K., Park, S.H., and Jang, Y.K. (2008). Molecular signatures associated with transformation and progression to breast cancer in the isogenic MCF10 model. Genomics 92, 419-428.
18. Robertson, K.D. (2005). DNA methylation and human disease. Nat. Rev. Genet. 6, 597-610.
19. Santner, S.J., Dawson, P.J., Tait, L., Soule, H.D., Eliason, J., Mohamed, A.N., Wolman, S.R., Heppner, G.H., and Miller, F.R. (2001). Malignant MCF10CA1 cell lines derived from premalignant human breast epithelial MCF10AT cells. Breast Cancer Res. Treat. 65, 101-110.
20. Song, J.H., Choi, C.H., Yeom, H.J., Hwang, S.Y., and Kim, T.S. (2006). Monitoring the gene expression profiles of doxorubicinresistant acute myelocytic leukemia cells by DNA microarray analysis. Life Sci. 79, 193-202.
21. Worsham, M.J., Pals, G., Schouten, J.P., Miller, F.R., Tiwari, N., van Spaendonk, R., and Wolman, S.R. (2006). High-resolution mapping of molecular events associated with immortalization, transforma-tion, and progression to breast cancer in the MCF10 model. Breast Cancer Res. Treat. 96, 177-186.
22. Xu, J., Zhou, J.Y., Tainsky, M.A., and Wu, G.S. (2007). Evidence that tumor necrosis factor-related apoptosis-inducing ligand induction by 5-Aza-2'-deoxycytidine sensitizes human breast cancer cells to adriamycin. Cancer Res. 67, 1203-1211.
23. Zhu, J.Q., Liu, J.H., Liang, X.W., Xu, B.Z., Hou, Y., Zhao, X.X., and Sun, Q.Y. (2008). Heat stress causes aberrant DNA methylation of H19 and Igf-2r on mouse balstocysts. Mol. Cells 25, 211-215.